Crossmark

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study

Crossref DOI link: https://doi.org/10.1186/s12933-020-01053-0

Published Online: 2020-06-13

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yang, Chun-Ting

Yang, Chen-Yi

Ou, Huang-Tz https://orcid.org/0000-0002-5475-7848
Kuo, Shihchen
Funding

Funding for this research was provided by:

Ministry of Science and Technology, Taiwan (107-2320-B-006-034)

National Institute of Diabetes and Digestive and Kidney Diseases (P30DK092926)
License Information

Text and Data Mining valid from 2020-06-13

Version of Record valid from 2020-06-13
More Information

Article History

Received: 25 February 2020

Accepted: 8 June 2020

First Online: 13 June 2020

Ethics approval and consent to participate

: The study was approved by the Institutional Review Board of National Cheng Kung University Hospital (A-EX-106-013).

: Not applicable.

: No competing interests to be declared.

Document is current

Any future updates will be listed below